Search Results - "Ifrah, Norbert"
-
1
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Published in The lancet oncology (01-08-2014)“…Summary Background Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia…”
Get full text
Journal Article -
2
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Published in The New England journal of medicine (15-09-2016)“…The addition of rituximab to every phase of treatment (induction, consolidation, and maintenance) in adults with acute lymphoblastic leukemia improves…”
Get full text
Journal Article -
3
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Published in Blood (19-05-2016)“…Acute myeloid leukemia (AML) with t(8;21) or inv(16) have been recognized as unique entities within AML and are usually reported together as core binding…”
Get full text
Journal Article -
4
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
Published in Blood (14-11-2013)“…Cancer cells require nutrients and energy to adapt to increased biosynthetic activity, and protein synthesis inhibition downstream of mammalian target of…”
Get full text
Journal Article -
5
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial
Published in Journal of clinical oncology (20-08-2018)“…Purpose To evaluate randomly the role of hyperfractionated cyclophosphamide (hyper-C) dose intensification in adults with newly diagnosed Philadelphia…”
Get full text
Journal Article -
6
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Published in Haematologica (Roma) (01-12-2016)“…Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To…”
Get full text
Journal Article -
7
IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ
Published in PloS one (08-02-2013)“…IL-34 is a recently identified cytokine that signals via the M-CSF receptor and promotes monocyte survival. Depending on the environment, monocytes can…”
Get full text
Journal Article -
8
Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
Published in Journal of clinical oncology (01-12-2013)“…The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia…”
Get full text
Journal Article -
9
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study
Published in Blood (16-07-2020)“…Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP)…”
Get full text
Journal Article -
10
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
Published in Blood (12-07-2018)“…Mutations in receptor tyrosine kinase/RAS signaling pathway genes are frequent in core-binding factor (CBF) acute myeloid leukemias (AMLs), but their…”
Get full text
Journal Article -
11
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Published in Journal of clinical oncology (20-02-2009)“…Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblastic leukemia (ALL) benefit from pediatric rather than adult…”
Get full text
Journal Article -
12
DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia
Published in Haematologica (Roma) (01-08-2019)“…The prognostic implications of genotype in T-cell acute lymphoblastic leukemia are incompletely understood. We performed comprehensive genetic and…”
Get full text
Journal Article -
13
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Published in Haematologica (Roma) (01-03-2016)“…In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain…”
Get full text
Journal Article -
14
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation
Published in Leukemia (01-07-2020)“…The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive…”
Get full text
Journal Article -
15
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
Published in Blood (18-11-2010)“…Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all cellular processes that are deregulated in AML cells should be…”
Get full text
Journal Article -
16
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Published in Blood (20-08-2009)“…The deregulation of translation markedly contributes to the malignant phenotype in cancers, and the assembly of the translation initiating complex eIF4F is the…”
Get full text
Journal Article -
17
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Published in Blood (01-01-2008)“…The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently activated, representing potential therapeutic targets in acute myeloid leukemia…”
Get full text
Journal Article -
18
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Published in Clinical cancer research (15-11-2010)“…The growth and survival of acute myeloid leukemia (AML) cells are enhanced by the deregulation of signaling pathways such as phosphoinositide 3-kinase…”
Get full text
Journal Article -
19
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL
Published in Molecular cancer (18-01-2023)“…The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation…”
Get full text
Journal Article -
20
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
Published in Blood cancer journal (New York) (26-01-2022)“…T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in…”
Get full text
Journal Article